checkAd

    DGAP-News  489  0 Kommentare Novavax Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering


    DGAP-News: Novavax, Inc. /
    Novavax Announces Exercise of Option to Purchase Additional Shares and
    Closing of Public Offering

    11.06.2014 / 22:01

    ---------------------------------------------------------------------

    GAITHERSBURG, Md., 2014-06-11 22:01 CEST (GLOBE NEWSWIRE) --
    Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused
    on the discovery, development and commercialization of recombinant nanoparticle
    vaccines and adjuvants, today announced the closing of the underwritten public
    offering priced on Thursday, June 5, 2014.

    The company issued 28,750,000 shares of its common stock, including 3,750,000
    shares pursuant to the underwriters' option to purchase additional shares. The
    shares were issued at $4.00 per share resulting in total gross proceeds from
    this offering of $115,000,000, before deducting the underwriters discount and
    offering expenses.

    Novavax intends to use a portion of the net proceeds from this offering to
    expand the clinical development of its RSV F-protein nanoparticle vaccine
    candidate through the initiation of a Phase 2 clinical trial in elderly
    subjects later this year. This trial has been added to the company's commitment
    to initiate RSV clinical trials in the pediatric and maternal immunization
    indications in the fourth quarter of 2014. Together, these three separate Phase
    2 trials will advance the development of the RSV F-protein vaccine candidate in
    all three of its primary indications, supporting the company's goal of
    accelerating the timelines to first approval. Additionally, the company intends
    to use certain of the net proceeds for general corporate purposes, the
    advancement of its influenza vaccine candidates and its pre-clinical research
    programs, manufacturing and process development activities, capital
    expenditures and other strategic purposes.

    Citigroup and JP Morgan acted as joint book-running managers of the offering.
    Piper Jaffray acted as lead manager, and FBR and Ladenburg Thalmann & Co. acted
    as co-managers.

    The shares described above were issued pursuant to a final prospectus
    supplement and accompanying prospectus. The company filed the final prospectus
    supplement relating to the offering with the Securities and Exchange Commission
    ('SEC') on June 9, 2014, which is available along with the accompanying
    prospectus filed with the SEC in connection with the company's shelf
    registration statement on Form S-3, previously declared effective by the SEC,
    on the SEC's website at www.sec.gov. Copies of the final prospectus supplement
    and the accompanying prospectus may be obtained from Citigroup and JP Morgan,
    Attention: Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island
    Seite 1 von 2


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-News Novavax Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering DGAP-News: Novavax, Inc. / Novavax Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering 11.06.2014 / 22:01 --------------------------------------------------------------------- GAITHERSBURG, Md., 2014-06-11 22:01 …

    Schreibe Deinen Kommentar

    Disclaimer